Skip to content

The Effect of Butanediol Ingestion on Skeletal Muscle Angiogenesis in Hypoxia

The Acute Effect of (R)-1,3-butanediol Ingestion on Post-exercise Skeletal Muscle Angiogenesis in Healthy Adults Under Normoxic and Hypoxic Conditions.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06472427
Enrollment
15
Registered
2024-06-25
Start date
2024-07-01
Completion date
2024-07-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiogenesis, Hypoxia, Ketosis

Keywords

Exercise, Recovery, Living high training low

Brief summary

This study specifically aims to elucidate the effects of intermittent exogenous ketosis (IEK) as well as hypoxia on muscular pro-angiogenic factors- after a 60-min HIIT bout in normoxia. Moreover, blood and muscle oxygenation status, as well as peripheral blood flow and cognitive function will be assessed.

Detailed description

After an exercise bout, angiogenesis is incredibly important in the recovery process as an increased number of capillaries enables higher metabolite transport to and from the working muscle. Often, a training strategy consists of living-high (sleeping at -stimulated- altitude) and training low (training at sea level). A decreased oxygen availability, also known as hypoxia, however poses an additional stress on the human body, potentially compromising the overall training efficiency. Ketones are recently found to increase angiogenesis in response to overload training (increased skeletal muscle capillarization and VEGF content) and to increase serum EPO concentrations. Therefore, the investigators want to evaluate the isolated and interactive effects of both ketones and hypoxia on post-exercise recovery and factors implicated in skeletal muscle angiogenesis, after training in normoxia. Moreover, a performance test will be performed after 7h of hypoxic or normoxic recovery by means of a simulated 15 min all-out time trial. During the 7h post-exercise window, biological samples are collected (muscle biopsies, venous blood samples, urine, capillary blood samples). Moreover, blood and muscle oxygenation, peripheral blood flow and cognitive function are assessed at regular timepoints.

Interventions

DIETARY_SUPPLEMENTNormoxic recovery and placebo (NPL)

Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w

DIETARY_SUPPLEMENTNormoxic recovery and ketones (NKE)

Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water

DIETARY_SUPPLEMENTHypoxic recovery and placebo (HPL)

Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w

DIETARY_SUPPLEMENTHypoxic recovery and ketones (HKE)

Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Both participants and investigators actively parttaking in the study are blinded. Participants are misinformed that all sessions will be hypoxic, in order to prevent identification of normoxic vs hypoxic conditions. Therefore, participants are also misinformed about the supplements, where they think they will receive 4 different compositions of ketones.

Intervention model description

1 session with normoxic post-exercise recovery, supplemented with placebo (NPL) 1 session with normoxic post-exercise recovery, supplemented with ketones (NKE) 1 session with hypoxic post-exercise recovery, supplemented with placebo (HPL) 1 session with hypoxic post-exercise recovery, supplemented with ketones (HKE)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

1. Written informed consent must be obtained prior to any experimental procedures 2. Biological male or biological females using oral contraception between 18 and 35 years old 3. Recreational or competitive cyclists performing regularly cycling training sessions with an average training volume of more than 6 hours per week 4. Good health status confirmed by a medical screening 5. Body Mass Index (BMI) between 18 and 25 kg/m2

Exclusion criteria

1. Any kind of injury/pathology that is a contra-indication for hypoxic exposure and/or to perform high-intensity exercise, evaluated by a sport medical screening 2. Intake of any medication or nutritional supplement that is known to affect exercise or performance. Intake will be assessed during recruitment and the sport medical screening. 3. Intake of analgesics, anti-inflammatory agents, or supplementary anti-oxidants, within two weeks of study participation. 4. Recent residence or training under hypoxia; more than 7 days exposure to altitude \> 1500 m during the 3 months preceding the study. 5. Blood donation within 3 months of study participation. 6. Habitual smoking 7. Pre-existing, diagnosed psychiatric conditions or anxiety 8. Females that are pregnant or are planning to be pregnant before the end of the study (end of May 2024) 9. Depression or anxiety as assessed by the Beck Depression Inventory 25 (Appendix 2) and Beck Anxiety Inventory 26 (Appendix 3). Only a score in the range of 'normal ups and downs' (score 1-10) for depression or 'minimal anxiety' (score 0-7) for anxiety are tolerated. 10. History of addiction or excessive caffeine/alcohol consumption assessed by a questionnaire (Appendix 4). 11. Any other reason that might pose undue risk to the participant, or introduce bias into the study outcomes, at the discretion of the research team.

Design outcomes

Primary

MeasureTime frameDescription
Post-exercise serum EPO concentrationsVenous blood samples are collected 10 minutes after the end of training as well as 3 hours, 5 hours and 7 hours later.Measured using ELISA on collected serum samples
Post-exercise muscle VEGF mRNA expressionMuscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.Measured using PCR on collected muscle biopsies

Secondary

MeasureTime frameDescription
Change in serum VEGF concentrationVenous blood samples are collected immediately (5 minutes) after the end of training, as well as 3hours, 5hours and 7hours later..Measured using ELISA on collected serum samples
Change in blood oxygenationContinuously measured starting 30 minutes after the end of exerciseuntil 7.5 hours laterMeasured using pulse oximetry with a sensor on the forehead
Change in peripheral blood flowMeasured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of the trainingMeasured using duplex ultrasonography
Exercise performancePerformed 7hours and 30minutes after the end of trainingMeasured as the average power output (W) during a 15 minutes all-out time trial
Change in skeletal muscle oxygenationMeasured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of training.Measured using NIRS with a sensor on the belly of the m. vastus lateralis (skeletal muscle)
Change in muscular VEGF concentrationMuscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.Measured using Western Blotting on muscle biopsies

Other

MeasureTime frameDescription
Change in citrate synthase as a marker of mitochondrial densityMuscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.Measured using an enzymatic essay

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026